AIM
ANIK icon

Advyzon Investment Management’s Anika Therapeutics ANIK Stock Holding History

Advyzon Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$723K Buy
49,855
+1,559
+3% +$18.1K 0.06% 290
2025
Q4 		$464K Buy
48,296
+28,160
+140% +$270K 0.05% 342
2025
Q3 		$189K Buy
+20,136
New +$192K 0.03% 468

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Advyzon Investment Management's ANIK Position: Q1 2026 in Review

Advyzon Investment Management increased its Anika Therapeutics (ANIK) stake by 3.2% in Q1 2026, buying an estimated $18.1K and bringing the position to 49,855 shares worth $723K. The position accounts for 0.06% of the portfolio, ranked #290.

Advyzon Investment Management first reported a position in ANIK in Q3 2025 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Advyzon Investment Management held 49,855 shares of Anika Therapeutics worth $723K as of Q1 2026.
  • Advyzon Investment Management bought 1,559 Anika Therapeutics shares in Q1 2026, an estimated $18.1K.
  • Anika Therapeutics made up 0.06% of Advyzon Investment Management's portfolio in Q1 2026, its #290 holding.
  • Advyzon Investment Management first reported a position in Anika Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Advyzon Investment Management's 13F filing for Q1 2026, filed 12 May 2026.